|
Jun 9
|
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
|
|
May 29
|
Qiagen (QGEN) Up 1.6% Since Last Earnings Report: Can It Continue?
|
|
May 29
|
Interim results of IGNAZ trial sheds positive light on felzartamab for IgAN
|
|
May 28
|
Is Biogen Inc.'s (NASDAQ:BIIB) Recent Price Movement Underpinned By Its Weak Fundamentals?
|
|
May 27
|
South Korea’s MFDS approves Eisai-Biogen’s LEQEMBI for Alzheimer’s
|
|
May 27
|
The Biggest Biotechnology Company in Europe
|
|
May 26
|
The Biggest Publicly Traded Biotech Company
|
|
May 24
|
Why Is Biogen (BIIB) Up 7.7% Since Last Earnings Report?
|
|
May 24
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
|
May 24
|
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
|
|
May 23
|
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
|
|
May 23
|
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
|
|
May 23
|
Biogen enters deal to acquire HI-Bio for $1.8bn
|
|
May 17
|
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
|
|
May 16
|
Biogen, Ionis shelve ALS drug following study failure
|
|
May 16
|
REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
|
|
May 16
|
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
|
|
May 16
|
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
|
|
May 15
|
Biogen Stock Continues Its 24% Sprint On A Twist In Alzheimer's Treatment
|
|
May 15
|
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
|